Články se zplnomocněním k veřejnému přístupu - Savino SciasciaDalší informace
Nedostupné nikde: 7
Antiphosphatidylserine/prothrombin antibodies: an update on their association with clinical manifestations of antiphospholipid syndrome
M Radin, SG Foddai, I Cecchi, E Rubini, K Schreiber, D Roccatello, ...
Thrombosis and haemostasis 120 (04), 592-598, 2020
Zplnomocnění: British Heart Foundation, Government of Italy
Differentiating between UCTD and early-stage SLE: from definitions to clinical approach
S Sciascia, D Roccatello, M Radin, I Parodis, J Yazdany, G Pons-Estel, ...
Nature Reviews Rheumatology 18 (1), 9-21, 2022
Zplnomocnění: US National Institutes of Health
16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome
S Sciascia, M Radin, I Cecchi, RA Levy, D Erkan
Lupus 30 (8), 1314-1326, 2021
Zplnomocnění: Government of Italy
Endothelial dysfunction and cardiovascular risk in lupus nephritis: New roles for old players?
D Mancardi, E Arrigo, M Cozzi, I Cecchi, M Radin, R Fenoglio, ...
European Journal of Clinical Investigation 51 (2), e13441, 2021
Zplnomocnění: Government of Italy
From inflammation to renal fibrosis: A one-way road in autoimmunity?
D Roccatello, HY Lan, S Sciascia, S Sethi, A Fornoni, R Glassock
Autoimmunity Reviews 23 (4), 103466, 2024
Zplnomocnění: Research Grants Council, Hong Kong
Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and …
ZB Erton, R K Leaf, D de Andrade, AE Clarke, MG Tektonidou, V Pengo, ...
Lupus 31 (14), 1770-1776, 2022
Zplnomocnění: US National Institutes of Health
Long-term follow-up of young adults with stroke
S Sciascia, ML Bertolaccini, O Ateka-Barrutia
JAMA 310 (3), 321-321, 2013
Zplnomocnění: US National Institutes of Health
Dostupné někde: 59
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome
GC Drosos, D Vedder, E Houben, L Boekel, F Atzeni, S Badreh, ...
Annals of the rheumatic diseases 81 (6), 768-779, 2022
Zplnomocnění: National Institute for Health Research, UK
14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends
ML Bertolaccini, O Amengual, L Andreoli, T Atsumi, CB Chighizola, ...
Autoimmunity reviews 13 (9), 917-930, 2014
Zplnomocnění: US National Institutes of Health, Versus Arthritis, UK
HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine …
K Schreiber, K Breen, H Cohen, S Jacobsen, S Middeldorp, S Pavord, ...
Seminars in thrombosis and hemostasis 43 (06), 562-571, 2017
Zplnomocnění: National Institute for Health Research, UK
The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort
M Radin, S Sciascia, D Erkan, V Pengo, MG Tektonidou, A Ugarte, ...
Seminars in arthritis and rheumatism 49 (3), 464-468, 2019
Zplnomocnění: US National Institutes of Health
Development of a new international antiphospholipid syndrome classification criteria phase I/II report: generation and reduction of candidate criteria
M Barbhaiya, S Zuily, Y Ahmadzadeh, MC Amigo, T Avcin, ...
Arthritis care & research 73 (10), 1490-1501, 2021
Zplnomocnění: US National Institutes of Health, British Heart Foundation
Ubiquinol effects on antiphospholipid syndrome prothrombotic profile: a randomized, placebo-controlled trial
C Pérez-Sánchez, MÁ Aguirre, P Ruiz-Limón, MC Ábalos-Aguilera, ...
Arteriosclerosis, thrombosis, and vascular biology 37 (10), 1923-1932, 2017
Zplnomocnění: Government of Spain
Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease
D Erkan, O Unlu, S Sciascia, HM Belmont, DW Branch, MJ Cuadrado, ...
Lupus 27 (3), 399-406, 2018
Zplnomocnění: US National Institutes of Health
Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort
S Sciascia, MJ Cuadrado, G Sanna, V Murru, D Roccatello, ...
Arthritis care & research 66 (12), 1915-1920, 2014
Zplnomocnění: US National Institutes of Health
Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION international clinical database and repository
E Sevim, D Zisa, D Andrade, S Sciascia, V Pengo, MG Tektonidou, ...
Arthritis care & research 74 (2), 324-335, 2022
Zplnomocnění: US National Institutes of Health, Natural Sciences and Engineering Research …
Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome
S Sciascia, C Lopez-Pedrera, I Cecchi, C Pecoraro, D Roccatello, ...
Rheumatology 55 (10), 1726-1735, 2016
Zplnomocnění: Government of Spain
Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome
C Pérez-Sánchez, I Arias-de la Rosa, MÁ Aguirre, M Luque-Tévar, ...
haematologica 103 (5), 908, 2018
Zplnomocnění: Government of Spain
The role of antirheumatics in patients with COVID-19
CB Nissen, S Sciascia, D de Andrade, T Atsumi, IN Bruce, RQ Cron, ...
The Lancet Rheumatology 3 (6), e447-e459, 2021
Zplnomocnění: National Institute for Health Research, UK
Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International …
GR de Jesús, S Sciascia, D Andrade, M Barbhaiya, M Tektonidou, ...
BJOG: An International Journal of Obstetrics & Gynaecology 126 (5), 656-661, 2019
Zplnomocnění: US National Institutes of Health
Informace o publikování a financování jsou automaticky vybírány počítačovým programem